Autonomix Medical, Inc. develops precision nerve-targeted medical device technology for diagnosing and treating diseases involving the nervous system. The company’s platform includes a catheter-based microchip sensing array intended to detect and differentiate neural signals and support transvascular approaches to peripheral nerve identification and treatment.
Recurring AMIX news centers on clinical and scientific updates for transvascular radiofrequency energy-based ablation, including pain mitigation research in pancreatic adenocarcinoma and peripheral nerve modulation. Company announcements also cover medical and interventional conference presentations, abstract selections, publication strategy, corporate presentations, and the clinical validation process for its minimally invasive nerve-targeted platform.
Autonomix Medical (AMIX) has received a Canadian patent protecting catheter-based technologies for accessing and treating tissue beyond the vessel wall. The Canadian Intellectual Property Office issued Patent No. 3,183,802, covering tools that operate inside a bodily passage and deploy probes into or through its wall.
The patent covers nerve-signal sensing at multiple sites, assessment of treatment completion, and systems that adjust stimulation or therapeutic energy using live physiological feedback. Related inventions already have patents in the United States and Europe. Autonomix's worldwide portfolio now includes 112 issued or pending patent applications, with portfolio expirations extending into the late 2030s.
Autonomix Medical (AMIX) completed an FDA pre-submission meeting that informed its proposed U.S. regulatory pathway for a standalone sensing platform.
The company believes the feedback supports a Class II 510(k) pathway, using a previously cleared reference device to demonstrate substantial equivalence. Autonomix targets potential U.S. clearance in approximately 15 months, subject to successful development and validation activities and FDA review.
Development and validation will continue alongside work on signal interpretation and advanced computational capabilities. The company believes clearance could provide a regulatory reference for future platform generations, including planned signal interpretation and procedural guidance.
Autonomix Medical (AMIX) received European Patent No. EP 4 233 700 B1 for technology assessing neural activity in the eye.
The patent, titled "Systems for Assessing Neural Activity in an Eye," covers systems and methods that monitor and analyze neural activity within the eye to assess autonomic nervous system activity. Its ocular measurements are designed to evaluate physiological responses. The technologies may support patient assessment, treatment guidance and procedural feedback across autonomic nervous system disorders and neuromodulation applications.
The grant expands the company's international portfolio of issued and pending patents.
Autonomix Medical (AMIX) appointed Sandra Cohen Kalter, former Vice President and Chief Regulatory Counsel at Medtronic, to its Board of Directors, adding more than four decades of MedTech, FDA regulatory and strategic transaction experience.
Kalter spent 20 years at Medtronic in senior legal regulatory roles, overseeing due diligence and integration for more than 27 acquisitions and supporting major platforms such as Symplicity Spyral Renal Denervation, Evolut TAVR, Micra Transcatheter Pacing System and PulseSelect Pulsed Field Ablation. She previously served 13 years as FDA/Healthcare Counsel at King & Spalding, advising on complex FDA matters. As a Board Member, she is expected to provide strategic guidance as Autonomix advances its investigational nerve-sensing and targeted therapy platform toward clinical development and potential industry partnerships.
Autonomix Medical (NASDAQ: AMIX) announced that two scientific abstracts featuring its transvascular nerve-targeting technology have been accepted for poster presentation at the CIRSE 2026 Annual Congress, held September 5-9, 2026, in Copenhagen, Denmark.
Both posters, presented by Dr. Robert Schwartz, address pain mitigation in pancreatic adenocarcinoma via transvascular RF ablation and the use of precision-guided transvascular technology for nervous system mapping, aligning with CIRSE’s theme of expanding access to minimally invasive, image-guided care.
Autonomix Medical (NASDAQ: AMIX) announced the issuance of U.S. Patent No. 12,714,780 on August 25, 2026, covering systems that integrate real-time physiological feedback, sensing and imaging with controlled delivery of therapeutic agents.
The patent protects medical systems using surgical instruments and controllers to regulate treatment based on feedback signals from targeted or surrounding tissues, including control of therapeutic fluid quantity and distribution. It encompasses applications where targeted tissue includes tumors and therapeutic fluids enable neural ablation to reduce cancer pain, and covers denervating and neuroblocking agents. The patent also addresses monitoring, imaging, stimulating and ablating neurological structures in the lower urinary tract via minimally invasive access routes, and is based on continuation applications dating back to 2012 and 2014.
Autonomix Medical (NASDAQ: AMIX) entered a warrant inducement agreement with an investor for the immediate cash exercise of July 2026 warrants to purchase 857,462 shares at $5.75 per share. The resale of these shares is covered by an effective Form S-3 registration statement.
Autonomix expects approximately $4.9 million in gross proceeds before fees. In return, the investor will receive unregistered Series E-1 and Series E-2 warrants, each for 535,913 shares, exercisable immediately at $6.25 per share and expiring five years after issuance. Closing is expected on or about August 26, 2026, subject to customary conditions.
Autonomix Medical (NASDAQ: AMIX) reported completion of a Good Laboratory Practice (GLP) preclinical study of its nerve-targeted medical device platform in porcine models, described as a significant regulatory milestone toward a planned submission to the U.S. Food and Drug Administration (FDA).
The study, run under FDA GLP standards, assessed safety, functionality and performance across multiple clinically relevant anatomical targets. Final histopathology and laboratory analyses were said to support previously reported positive safety and performance outcomes. Autonomix expects these data to form a key component of its regulatory package and to support future FDA submissions as it progresses from preclinical development toward clinical-stage execution.
Autonomix Medical (NASDAQ: AMIX) announced that its Co-Founder and Chief Medical Officer, Dr. Robert Schwartz, has been selected to receive the 2026 Cardiovascular Tech Forum (CTF) Lifetime Achievement Award. The honor recognizes his long-standing contributions to cardiovascular medicine, medical technology innovation and entrepreneurial leadership.
Dr. Schwartz will be formally honored at Octane’s 2026 Cardiovascular Tech Forum on September 18, 2026, in Newport Beach, California. According to Autonomix, he has authored more than 500 scientific publications, holds over 200 patents, and has founded multiple medtech companies, including co-inventing the Watchman device, later acquired by Boston Scientific. Autonomix highlights that his experience supports the company’s efforts to advance precision nerve-targeted treatments.
Autonomix Medical (NASDAQ: AMIX) announced issuance of U.S. Patent No. 12,433,670, titled “Systems and Methods for Treating Cancer and/or Augmenting Organ Function.” The patent expands protection for minimally invasive technologies that sense, map and selectively target nerves linked to tumors, cancer-related pain, organ function and autonomic nervous system disorders.
The patent covers catheter-based microsurgical tools that record neural signals and deliver energy or therapeutic agents to block or modulate identified nerves. According to Autonomix Medical, it broadens the company’s precision neuromodulation platform and complements previously issued patents in autonomic assessment, neural sensing, treatment guidance and transvascular neuromodulation.